Article Information
History
- December 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Camilo C. Roa Jr.1,
- Mari Rose A. de Los Reyes2,
- Eric Plennevaux3,*,
- Igor Smolenov4,
- Branda Hu4,
- Faith Gao4,
- Hannalyn Ilagan4,
- Donna Ambrosino5,
- George Siber6 and
- Ralf Clemens7
- 1Department of Physiology, Philippine General Hospital, University of the Philippines, Manila 1000, Philippines
- 2Las Pinas Doctors Hospital, Las Pinas City, Philippines
- 3Clover Biopharmaceuticals, Cambridge, UK
- 4Clover Biopharmaceuticals, Boston, MA, USA
- 5Independent Advisor, Stuart, FL, USA
- 6Independent Advisor, New York, NY, USA
- 7Global Research in Infectious Diseases, Rio de Janeiro, Brazil
- ↵*Corresponding author:
Dr. Eric Plennevaux, 124 route de sainte Consorce, 69280 Marcy l’Etoile, France, Tel: +33 674938689, e-mail: eric.plennevaux{at}cloverbiopharma.com
Posted December 06, 2022.
Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine
